MGCD0103: Phase II started

MethylGene and Celgene began an open-label, international Phase II trial (Trial 013) evaluating oral MGCD0103 plus subcutaneous Vidaza azacitidine, MGCD0103 alone or Vidaza alone in 180 patients with...